The 36-month beta value for NLSP is also noteworthy at -0.52. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NLSP is 28.57M, and at present, short sellers hold a 1.91% of that float. The average trading volume of NLSP on July 29, 2024 was 10.16M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NLSP) stock’s latest price update
The stock price of NLS Pharmaceutics Ltd (NASDAQ: NLSP) has jumped by 37.84 compared to previous close of 0.19. Despite this, the company has seen a gain of 45.34% in its stock price over the last five trading days. accesswire.com reported 2024-07-29 that The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem’s allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support for the transaction from shareholders representing more than 40% of their respective outstanding shares ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / July 29, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (“NLS”), a biopharmaceutical company.
NLSP’s Market Performance
NLSP’s stock has risen by 45.34% in the past week, with a monthly rise of 9.13% and a quarterly rise of 91.59%. The volatility ratio for the week is 12.44% while the volatility levels for the last 30 days are 17.31% for NLS Pharmaceutics Ltd The simple moving average for the last 20 days is 32.62% for NLSP’s stock, with a simple moving average of -25.03% for the last 200 days.
NLSP Trading at 49.82% from the 50-Day Moving Average
After a stumble in the market that brought NLSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.27% of loss for the given period.
Volatility was left at 17.31%, however, over the last 30 days, the volatility rate increased by 12.44%, as shares surge +19.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +78.08% upper at present.
During the last 5 trading sessions, NLSP rose by +44.28%, which changed the moving average for the period of 200-days by -66.67% in comparison to the 20-day moving average, which settled at $0.1996. In addition, NLS Pharmaceutics Ltd saw -55.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NLSP
The total capital return value is set at 1.94.
Based on NLS Pharmaceutics Ltd (NLSP), the company’s capital structure generated -0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -5.93. The debt to equity ratio resting at -0.18. The interest coverage ratio of the stock is -81.34.
Currently, EBITDA for the company is -11.8 million with net debt to EBITDA at -0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.23.
Conclusion
In summary, NLS Pharmaceutics Ltd (NLSP) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
